key: cord-0288320-q9d011pd authors: Aziz, N. A.; Santos, M. L. S.; Breteler, M. M. B. title: The association between SARS-CoV-2 infection and neuronal damage: A population-based nested case-control study date: 2021-09-05 journal: nan DOI: 10.1101/2021.09.02.21263019 sha: 4fb7f281033c7ffd9ddf463fc2035f88c0e898b4 doc_id: 288320 cord_uid: q9d011pd Objective: To assess whether severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is associated with changes in plasma levels of neurofilament light chain (NfL), an extremely sensitive marker of neuroaxonal damage, in community-dwelling individuals. Setting: This study was embedded within the Rhineland Study, an ongoing community-based cohort study in Bonn, Germany Design: Cross-sectional nested case-control study. Participants: Participants were selected based on results from a previously conducted seroprevalence survey within the framework of the Rhineland Study. Cases were defined as those individuals who had had two positive confirmatory test results, including a recombinant spike-based immunofluorescence assay and a plaque reduction neutralization test (N=21). As controls, a random sample of individuals with a negative ELISA test result (Controls I, N=1117), and those with a borderline or positive ELISA test result who failed confirmatory testing (Controls II, N=68), were selected. Outcome measures: Plasma levels of NfL at the time of measurement, as well as change in plasma NfL levels compared to previously measured pre-pandemic levels Results: After adjustment for age, sex and batch effects, serologically confirmed SARS-CoV-2 infection was neither associated with cross-sectional NfL levels, nor with the magnitude of change from pre-pandemic levels, compared to either of the two control groups. Similarly, after adjustment for age, sex and batch effects, self-reported neurological symptoms (including altered sense of smell or taste, headache, myalgia and fever) were not associated with changes in NfL levels in participants with a serologically confirmed SARS-CoV-2 infection (all p [≥] 0.56). Conclusions: Our findings indicate that mild-to-moderate coronavirus disease-19 is unlikely to be associated with a clinically relevant degree of neuroaxonal damage, even in those cases associated with neurological symptoms. Neurological signs and symptoms are reported in more than one-third of coronavirus disease-19 (COVID-19) patients, sometimes even as the presenting or sole manifestation of the disease. 1, 2 Although (para-)infectious neuronal injury has been demonstrated in hospitalized cases with severe to critical illness, [3] [4] [5] [6] [7] [8] [9] it is still unclear whether it also occurs in patients with mild-to-moderate disease in whom neurological symptoms are also very common. 1 Therefore, we assessed whether severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is associated with changes in plasma levels of neurofilament light chain (NfL), an ultrasensitive marker of neuroaxonal damage, in community-dwelling individuals. Between April 24 th and June 30 th , 2020, we conducted a seroprevalence survey embedded within the Rhineland Study, an ongoing community-based cohort study in Bonn, Germany, the results of which have been published previously. 10 SARS-CoV-2 antibodies were measured with an enzyme-linked immunosorbent assay (ELISA), followed by confirmatory testing of borderline and positive test results with a recombinant spike-based immunofluorescence assay and a plaque reduction neutralisation test. 10 We defined cases as those participants who had two positive confirmatory test results (N=21). As controls we selected a random sample of individuals with a negative ELISA (Controls I, N=1117), and those with a borderline or positive ELISA who failed confirmatory testing (Controls II, N=68). Plasma NfL levels were measured with the Quanterix Simoa NF-light® assay in samples collected during the serosurvey, as well as in samples from the same individuals collected between 2016 and 2019. Generalized linear (mixed-effect) models were used to assess the association between SARS-CoV-2 infection and log-transformed NfL levels, both cross-sectionally and as change from pre-pandemic levels. Table 1 . After adjustment for age, sex and batch effects, serologically confirmed SARS-CoV-2 infection was neither associated with cross-sectional NfL levels, nor with the magnitude of change from pre-pandemic levels, compared to either of the two control groups (Figure 1) . Similarly, after adjustment for age, sex and batch effects, self-reported neurological symptomsincluding altered sense of smell or taste, headache, myalgia and feverwere not associated with changes in NfL levels in participants with a serologically confirmed SARS-CoV-2 infection (all p ≥ 0.56). Sensitivity analysis by excluding NfL levels above 4 standard deviations from the control groups did not materially change any of the results (data now shown). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 5, 2021. ; https://doi.org/10.1101/2021.09.02.21263019 doi: medRxiv preprint We present the first population-based study of the association between SARS-CoV-2 infection and neuronal injury. By implementing a serosurvey with a rigorous multi-tiered testing approach in an ongoing large prospective population-based cohort study, we were able to minimize the risk of falsepositives and take advantage of existing bio-samples collected before the start of the pandemic. 10 In community-dwelling individuals with mild-to-moderate symptoms, we found no association between serologically confirmed recent infections by SARS-CoV-2 and neuroaxonal damage, neither in comparison to individuals without evidence of a recent infection, nor in comparison to individuals with probable cross-reactive antibodies against other viruses. Our results parallel those from a recent cross-sectional study in 2652 children, of whom 148 had serological evidene of a SARS-CoV-2 infection, which also did not find changes in blood NfL levels in pediatric cases with asysmptomatic to moderate COVID-19. 11 However, these and our results contrast with those of a previous small-scale study that reported increased serum NfL levels in health care workers with mild-to-moderate COVID-19. 12 This discrepancy may be accounted for by the fact that this other study did not assess intra-individual changes in NfL levels, only included a small reference group, and the results may have been confounded by incomplete information on participants' age. 12 Reports of neuroaxonal damage in hospitalized patients with severe COVID-19 may thus reflect neuronal injury due to dyshomeostasis and hypercoagulation engendered by the systemic infection and inflammation without direct viral neuroinvasion. [3] [4] [5] [6] [7] [8] [9] Potential limitations of our study include the relatively small number of cases with a serologically confirmed SARS-CoV-2 infection and lack of data on the exact timing of the infection in seropositive individuals. However, given that the samples were collected shortly after the start of the pandemic in Germany, and the relatively long half-life of NfL that is estimated to be up to a few weeks, 13 it is unlikely that we would have missed any substantial or progressive post-infectious elevations of serum NfL levels. Our findings indicate that mild-to-moderate COVID-19 is unlikely to be associated with a clinically relevant degree of neuroaxonal damage, even in those cases associated with neurological symptoms like olfactory and gustatory dysfunction, headache and myalgia. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 5, 2021. The Rhineland Study's dataset is not publicly available because of data protection regulations. Access to data can be provided to scientists in accordance with the Rhineland Study's Data Use and Access Policy. Requests for further information or to access the Rhineland Study's dataset should be directed to RS-DUAC@dzne.de. Foundation) under Germany´s Excellence Strategy, grant number EXC 2151 -390873048. The authors report no conflicts of interest. Approval to undertake the Rhineland Study was obtained from the ethics committee of the University of Bonn, Medical Faculty (reference ID: 338/15). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 5, 2021. ; https://doi.org/10.1101/2021.09.02.21263019 doi: medRxiv preprint Table 1 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 5, 2021. ; https://doi.org/10.1101/2021.09.02.21263019 doi: medRxiv preprint Neurological associations of COVID-19 Neurological manifestations as primary presentation of COVID-19 in hospitalized patients Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease Cerebrospinal fluid findings in neurological diseases associated with COVID-19 and insights into mechanisms of disease development CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms: A Case Series Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19 Biomarkers for central nervous system injury in cerebrospinal fluid are elevated in COVID-19 and associated with neurological symptoms and disease severity Blood neurofilament light chain and total tau levels at admission predict death in COVID-19 patients Blood neurofilament light concentration at admittance: a potential prognostic marker in COVID-19 Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: Results from a population-based study in Bonn Serum neurofilament light chain (sNfL) values in a large cross-sectional population of children with asymptomatic to moderate COVID-19 Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19 Serial Sampling of Serum Protein Biomarkers for Monitoring Human Traumatic Brain Injury Dynamics: A Systematic Review